Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

Next Previous
Trial Profile

The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NB 001 (Primary)
  • Indications Herpes labialis
  • Focus Therapeutic Use
  • Sponsors BlueWillow Biologics; NanoBio Corporation

    • Most Recent Events

    • 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
    • 28 Oct 2008 Data presented at the annual ICAAC/IDSA meeting in Washington, D.C, USA.
    • 17 Mar 2008 Primary endpoint met; results reported in a NanoBio Corporation media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top